News

News Archive

NewAmsterdam Pharma and the Menarini Group Sign Licensing Deal to Commercialize Obicetrapib in Europe

NewAmsterdam Pharma and the Menarini Group Sign Licensing Deal to Commercialize Obicetrapib in Europe

Naarden, the Netherlands, Miami, USA and Florence, Italy; June 28, 2022 – NewAmsterdam Pharma (NewAmsterdam), a clinical-stage company focused on the research and development of...
The XXVI Fair Play Menarini International Award opens with a press conference at CONI

The XXVI Fair Play Menarini International Award opens with a press conference at CONI

ROME – The opening whistle has blown for the XXVI Fair Play Menarini International Award. This morning, the Salone d’Onore at CONI (the Italian National Olympic Committee) in...
Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant

Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant

Florence, Italy and Boston, Mass., June 22, 2022 – The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the...
Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Florence, Italy and Boston, Mass., June 6, 2022 - The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the...

Select a Year from the Archive

Our values

Our values

Everyday we put our values into action. 4 values, which have given life to Menarini and have shaped its history.

Read More

Our values

Follow our blog

Discover our stories from all over the world

Read More